Evaluation of a Therapeutic Education Program for Pregnant Women With a First Child Diagnosed With an Autism Spectrum Disorder (AUTMER)
Primary Purpose
Child Psychiatry
Status
Not yet recruiting
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
The M.E.R. program
Sponsored by
About this trial
This is an interventional prevention trial for Child Psychiatry focused on measuring autism spectrum disorder, therapeutic education, prevention, pregnancy
Eligibility Criteria
Inclusion Criteria:
- Mothers of children with a diagnosis of ASD, in pregnancy (before the 26th week of amenorrhea);
- The diagnosis of ASD of the older child has been made, according to the DSM IV-TR or DSM 5 criteria, formalized by a diagnostic evaluation including: the Autism Diagnostic Observation Schedule ADOS, the Autism Diagnostic Interview - Revised version (ADI-R) accompanied by a cognitive evaluation of the child (Wechsler/Mullen Scales of Early Learning/Raven's Progressive Matrices);
- Informed consent from mother and sec
Exclusion Criteria:
- Presence of a clearly identified and unstabilized severe psychiatric disorder in the mother (confirmed by medical interview and DIGS questionnaire conducted at the time of the inclusion visit) and/or intellectual disability;
- Engagement in another form of individual therapeutic intervention.
- Refusal of either parent (for child assessment, primary criterion)
- Parents not proficient in French language
- Persons (mother or second parent) under legal protection, guardianship or trusteeship, persons deprived of liberty, under court protection, under psychiatric care, under constraint, admitted to a health or social institution for purposes other than research
- Persons with cognitive disorders or intellectual disabilities
Sites / Locations
- Hôpital Robert Debré
Arms of the Study
Arm 1
Arm 2
Arm Type
No Intervention
Experimental
Arm Label
control group
experimental group
Arm Description
Pregnant women followed by the center in the period before the intervention is implemented (the start of which is determined by randomization)
Pregnant women followed by the center during the period after the intervention is implemented (the start of which is determined by randomization)
Outcomes
Primary Outcome Measures
Manchester Assessment of Caregiver-infant Interaction (MACI) "caregiver non-directiveness" subscore
mother-baby interaction in the experimental group versus the control group at 5 months postpartum.
This subscore is the most sensitive to intervention and predictive of ASD diagnosis.
Secondary Outcome Measures
Pregnancy-Related Anxiety Questionnaire-Revised2 (PRAQ-R2) subscore
To evaluate the effect of the MER program on maternal anxiety related to pregnancy
Pregnancy-Related Anxiety Questionnaire-Revised2 (PRAQ-R2) subscore
To evaluate the effect of the MER program on maternal anxiety related to pregnancy
Appraisal of Life Events Scale (ALES)
Perceived pregnancy-related stress in the mother.scale with a list of adjectives, rated on a five-point Likert scale)
Appraisal of Life Events Scale (ALES)
Perceived pregnancy-related stress in the mother.scale with a list of adjectives, rated on a five-point Likert scale
Edimburgh Postnatal Depression Scale (EPDS)
used to assess the risk of postnatal depression and is useful for identifying the presence of anxiety symptoms.The threshold retained for the French validation is 10.5, above which a depression is possible and below which the risk is very low.
quality of life score-Bref (WhoQol-Bref)
WHOQOL-BREF includes 26 items that measure the following broad domains: physical health, psychological health, social relationships and environment.
parental anxiety score (HAM)
hetero-questionnaire with 14 items, measuring both the psychic (mental agitation and psychological distress) and somatic (physical complaints related to anxiety) expression of anxiety. Each item is rated on a Likert scale from 0 to 4 (total range 0-56, where <17= mild anxiety; 18-24= mild to moderate; 25-30 moderate to severe)
mother's intelligence quotient
measured by Raven's Progressive Matrices
Social Responsiveness Scale (SRS)
to refine the evaluation of social difficulties in a dimensional way
Wechsler Mullen scale
developmental level of the ASD child
Full Information
NCT ID
NCT05104112
First Posted
October 11, 2021
Last Updated
December 7, 2022
Sponsor
Assistance Publique - Hôpitaux de Paris
1. Study Identification
Unique Protocol Identification Number
NCT05104112
Brief Title
Evaluation of a Therapeutic Education Program for Pregnant Women With a First Child Diagnosed With an Autism Spectrum Disorder
Acronym
AUTMER
Official Title
Evaluation of a Therapeutic Education Program for Pregnant Women With a First Child Diagnosed With an Autism Spectrum Disorder (ASD)
Study Type
Interventional
2. Study Status
Record Verification Date
November 2022
Overall Recruitment Status
Not yet recruiting
Study Start Date
February 2023 (Anticipated)
Primary Completion Date
August 2026 (Anticipated)
Study Completion Date
August 2026 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Assistance Publique - Hôpitaux de Paris
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Autism Spectrum Disorder (ASD) is a heterogeneous set of severe developmental abnormalities of the nervous system characterized by deficits affecting social interactions and verbal and non-verbal communication, as well as the presence of restricted interests, repetitive behaviors, and atypical sensory manifestations . ASD affects approximately 1% of the general population (Elsabbagh et al., 2012). Studies of siblings of individuals with ASD show that ASD is present in 7-20% of the offspring in families where a child has had a diagnosis of ASD and this prevalence increases if there are two diagnosed children.
Several studies show the benefits of interventions targeting parents' interaction strategies in the early phases of development of infants at high risk for ASDs, in reducing the risk itself or its severity. Very early intervention, due to the presence of significant brain plasticity at these stages, may be particularly effective in changing these emerging trajectories, from a "preventive intervention" perspective that would aim to mitigate developmental risk and alter prodromal symptom trajectories, rather than eliminate a condition.
Our hypothesis is that the implementation of a specific therapeutic education program during a new pregnancy in the mother of a child with a diagnosis of ASD (MER Program) could improve the mother's well-being, increase parenting communication skills, and thereby improve interaction with the newborn at high risk for ASD. If the infant is affected, it may also reduce the symptoms of the disorder. Indirectly, it could also improve the well-being of the other parent involved in the interaction.
Detailed Description
Randomized controlled trial with deferred start, French multicenter stepped-wedge type.
The start date of the intervention in each center will be done by randomization, defining 2 periods: a control period located before the start of the intervention, and an experimental period located after the start of the intervention.
This design allows the principal investigating team to train the centers associated in turn with the intervention, and to have a control group with structured follow-up but without intervention.
All subjects will be included before 26 ADT and assigned to the control or experimental group, depending on the time of inclusion and the randomization of the center to which they belong.
The follow-up will be conducted in 2 phases: 1. during pregnancy and 2. After the birth of the child.
Subjects included were pregnant women who already had a child with an ASD diagnosis, the second parent if present, and the newborn at risk for an ASD diagnosis.
The primary objective of this study is to evaluate the effect of an innovative therapeutic education program (the MER program) versus control in pregnant women with a first child followed for ASD on the quality of interaction strategies of the mother-infant dyad at 10 months postpartum.
The primary endpoint was the caregiver non-directiveness subscore of the Manchester Assessment of Caregiver-infant Interaction (MACI) scale at 10 months postpartum. This subscore is both the most sensitive to intervention and predictive of ASD diagnosis.
The first secondary objective is the evaluation of the effect of the MER versus control program on:
maternal pregnancy-related anxiety (PRAQ-R2 score) ;
Anxious and depressive symptomatology and quality of life (WhoQoL-Bref score) in the mother and the second parent during pregnancy (EPDS score) and up to 20 months of age of the newborn (HAM-Anxiety and HAM-Depression scores);
perceived stress related to pregnancy (ALES score)
mother-infant interaction at 10 and 20 months (MACI score and subscore);
autistic signs in at-risk infants at 20 months (ADOS Toddler score);
The second secondary objective was to study variables that could impact the effect of the intervention, including
adherence: compliance with sessions, satisfaction of participants (PEI-Parent score) ;
other variables that could modulate the effect of the intervention: sociodemographic variables (socioeconomic level, family configuration, number of children); clinical profile of the mother (intellectual efficiency (Raven's PM score), psychiatric comorbidities (DIGS, SRS score)); clinical profile of the child already diagnosed (ADI-R and ADOS score; developmental level); clinical profile of the infant at risk (gestational age, MSEL, IBQ-R and ECBQ scores).
The third secondary objective was to describe the barriers and levers to the implementation of the intervention.
Characteristics related to the implementation of the intervention (recruitment, uptake, fidelity, and implementation) will be collected, as well as the profile of mothers who did not participate in the project.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Child Psychiatry
Keywords
autism spectrum disorder, therapeutic education, prevention, pregnancy
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
A pragmatic, multicenter, randomized, delayed-onset, stepped-wedge cluster study.
Masking
Outcomes Assessor
Masking Description
To ensure blinding, the primary endpoint, assessed on video, will be measured at the end of the study by a blinded investigator from the randomization group and from a different center than the inclusion center.
Allocation
Randomized
Enrollment
160 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
control group
Arm Type
No Intervention
Arm Description
Pregnant women followed by the center in the period before the intervention is implemented (the start of which is determined by randomization)
Arm Title
experimental group
Arm Type
Experimental
Arm Description
Pregnant women followed by the center during the period after the intervention is implemented (the start of which is determined by randomization)
Intervention Type
Other
Intervention Name(s)
The M.E.R. program
Intervention Description
The M.E.R program is a therapeutic education intervention for mothers of children with ASD during a new pregnancy. This program, which is a pilot in France and in Europe, involves several dimensions, both pedagogical and behavioral (strategies for stimulating the baby, use of specific communication and interaction tools) and psychological (reduction of stress, anxiety, etc. in the mother).
It includes 8 individual interviews of 1h30 every 15 days. The first and the last one are for evaluation purposes, the 6 intermediate sessions constitute the accompaniment. The structure of the program and the sessions are based on what is recommended in therapeutic education. The sessions can take place on the hospital site or at home.
Primary Outcome Measure Information:
Title
Manchester Assessment of Caregiver-infant Interaction (MACI) "caregiver non-directiveness" subscore
Description
mother-baby interaction in the experimental group versus the control group at 5 months postpartum.
This subscore is the most sensitive to intervention and predictive of ASD diagnosis.
Time Frame
5 months after delivery
Secondary Outcome Measure Information:
Title
Pregnancy-Related Anxiety Questionnaire-Revised2 (PRAQ-R2) subscore
Description
To evaluate the effect of the MER program on maternal anxiety related to pregnancy
Time Frame
between 11 weeks and 26 weeks of gestation
Title
Pregnancy-Related Anxiety Questionnaire-Revised2 (PRAQ-R2) subscore
Description
To evaluate the effect of the MER program on maternal anxiety related to pregnancy
Time Frame
at 3 months after intervention
Title
Appraisal of Life Events Scale (ALES)
Description
Perceived pregnancy-related stress in the mother.scale with a list of adjectives, rated on a five-point Likert scale)
Time Frame
between 11 weeks and 26 weeks of gestation
Title
Appraisal of Life Events Scale (ALES)
Description
Perceived pregnancy-related stress in the mother.scale with a list of adjectives, rated on a five-point Likert scale
Time Frame
at 3 months after intervention
Title
Edimburgh Postnatal Depression Scale (EPDS)
Description
used to assess the risk of postnatal depression and is useful for identifying the presence of anxiety symptoms.The threshold retained for the French validation is 10.5, above which a depression is possible and below which the risk is very low.
Time Frame
10 months after birth
Title
quality of life score-Bref (WhoQol-Bref)
Description
WHOQOL-BREF includes 26 items that measure the following broad domains: physical health, psychological health, social relationships and environment.
Time Frame
10 months after birth
Title
parental anxiety score (HAM)
Description
hetero-questionnaire with 14 items, measuring both the psychic (mental agitation and psychological distress) and somatic (physical complaints related to anxiety) expression of anxiety. Each item is rated on a Likert scale from 0 to 4 (total range 0-56, where <17= mild anxiety; 18-24= mild to moderate; 25-30 moderate to severe)
Time Frame
10 months after birth
Title
mother's intelligence quotient
Description
measured by Raven's Progressive Matrices
Time Frame
between 11 weeks and 26 weeks of gestation
Title
Social Responsiveness Scale (SRS)
Description
to refine the evaluation of social difficulties in a dimensional way
Time Frame
between 11 weeks and 26 weeks of gestation
Title
Wechsler Mullen scale
Description
developmental level of the ASD child
Time Frame
between 11 weeks and 26 weeks of gestation
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Mothers of children with a diagnosis of ASD, in pregnancy (before the 26th week of amenorrhea);
The diagnosis of ASD of the older child has been made, according to the DSM IV-TR or DSM 5 criteria, formalized by a diagnostic evaluation including: the Autism Diagnostic Observation Schedule ADOS, the Autism Diagnostic Interview - Revised version (ADI-R) accompanied by a cognitive evaluation of the child (Wechsler/Mullen Scales of Early Learning/Raven's Progressive Matrices);
Informed consent from mother and sec
Exclusion Criteria:
Presence of a clearly identified and unstabilized severe psychiatric disorder in the mother (confirmed by medical interview and DIGS questionnaire conducted at the time of the inclusion visit) and/or intellectual disability;
Engagement in another form of individual therapeutic intervention.
Refusal of either parent (for child assessment, primary criterion)
Parents not proficient in French language
Persons (mother or second parent) under legal protection, guardianship or trusteeship, persons deprived of liberty, under court protection, under psychiatric care, under constraint, admitted to a health or social institution for purposes other than research
Persons with cognitive disorders or intellectual disabilities
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Anita Beggiato, PHD
Phone
0033140032000
Email
anita.beggiato@aphp.fr
First Name & Middle Initial & Last Name or Official Title & Degree
Richard Delorme, PHD
Phone
0033140034130
Email
richard.delorme@aphp.fr
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Anita Beggiato, PHD
Organizational Affiliation
APHP
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hôpital Robert Debré
City
Paris
ZIP/Postal Code
75019
Country
France
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Anita Beggiato, PHD
Phone
01 40 03 20 00
Email
anita.beggiato@aphp.fr
12. IPD Sharing Statement
Learn more about this trial
Evaluation of a Therapeutic Education Program for Pregnant Women With a First Child Diagnosed With an Autism Spectrum Disorder
We'll reach out to this number within 24 hrs